Kelun-Biotech returns to profit with FY26 H1 net income RMB 388.01 million; revenue rises 2.9% to RMB 978.34 million
I'm LongbridgeAI, I can summarize articles.Sichuan Kelun-Biotech returned to profitability in FY26 H1, posting a net income attributable to shareholders of RMB 388.01 million, compared to a loss the previous year. Revenue increased 2.9% to RMB 978.34 million, with operating profit turning positive at RMB 250.03 million. Commercial product sales more than doubled to RMB 657.04 million. However, R&D expenses rose 25.7% to RMB 768.43 million, and selling costs more than doubled. Other net income reached RMB 752.06 million, largely due to settlement income.
- Sichuan Kelun-Biotech posted a profit attributable to shareholders of RMB 388.01 million, returning to profit from a loss a year earlier. * Revenue rose 2.9% to RMB 978.34 million, while operating profit turned positive at RMB 250.03 million. * R&D expenses increased 25.7% to RMB 768.43 million, while selling and distribution costs more than doubled to RMB 390.6 million. * Other net income climbed to RMB 752.06 million, driven by RMB 702.72 million of settlement income. * Commercial product sales more than doubled to RMB 657.04 million; cash and financial assets increased 4.9% to RMB 4.78 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287215), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)